RecruitingPhase 1

A Study of MK-7240 in Healthy Participants (MK-7240-009)

Australia330 participantsStarted 2026-03-05

Plain-language summary

The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria The main inclusion criteria include but are not limited to the following: * Has a body-mass index (BMI) between 18 and 32 kg/m\^2 Exclusion Criteria The main exclusion criteria include but are not limited to the following: * Has a history of more than 1 episode of herpes zoster infection or history of disseminated herpes zoster infection * Has a history of or current active tuberculosis (TB) infection or history of latent TB that was not fully treated

What they're measuring

Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Tulisokibart

Timeframe: At designated timepoints up to 14 weeks

Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Tulisokibart

Timeframe: At designated timepoints up to 14 weeks

Maximum Plasma Concentration (Cmax) of Tulisokibart

Timeframe: At designated timepoints up to 14 weeks

Trial details

NCT IDNCT07405177

SponsorMerck Sharp & Dohme LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-09-03

Contact for this trial

Toll Free Number

1-888-577-8839 Trialsites@msd.com

View on ClinicalTrials.gov More Healthy trials